In vivo assessment of captopril selectivity of angiotensin I-converting enzyme inhibition: Differential inhibition of acetyl-Ser-Asp-Lys-Pro and angiotensin I hydrolysis

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 3, 1999, Pages 1257-1261

  Junot, Christophe ^a   Menard, Joel ^b   Gonzales, Marie Francoise ^b   Michaud, Annie ^c   Corvol, Pierre ^c   Ezan, Eric ^a  

^a Institut National de la Recherche Agronomique   (France)

^b Inst Natl S et de la Rech U129   (France)

^c l'alimentation et l'Environnement   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN I; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; CELL PROTECTION; DRUG POTENCY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HEMATOPOIETIC STEM CELL; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; MALE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN I; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CAPTOPRIL; HYDROLYSIS; INJECTIONS, INTRAVENOUS; KINETICS; MALE; OLIGOPEPTIDES; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, INBRED SHR; RENIN; SUBSTRATE SPECIFICITY; TIME FACTORS;

EID: 0032995591     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM, Lenfant M, Corvol P and Menard J (1996) Acute angiotensin-convrrting enzyme inhibition increases the plasma levels of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 97:1-6.
2. Azizi M, Ezan E, Nicolet L, Grognet JM and Ménard J (1997) High plasma level of acetyl-seryl-aspartyl-lysyl-proline: A new marker of chronic angiotensin-converting enzyme inhibition. Hypertension 30:1015-1019.
3. Bevilacqua M, Vago T, Rogolino A, Conci F, Santoli E and Norbiato G (1996) Affinity of angiotensin I-converting enzyme (ACE) inhibitors for N- and C-binding sites of human ACE is different in heart, lung, arteries and veins. J Cardiovasc Pharmacol 28:494-499.
4. Carde P, Chastang C, Goncalves E, Mathieu-Tubiana N, Vuillemin E, Delwail V, Corbion O, Vekhoff A, Isnard F, Ferrero JM, Garcia-Giralt E, Gimonet JF, Stoppa AM, Leger-Picherit E, Fadel E, Monpezat JP, Munck JN, Domenge C, Khayat D, Guilhot F, Monnier A, Zittoun R, Brun B, Namer M, Maraninchi D, Deschamp de Paillette E, Guigon M and Najman A (1992) Seraspenide (AcSDKP): Etude en phase I-II d'un inhibiteur de l'hématopoïèse protégeant de la toxicité de monochimiothérapies aracytine et ifosfamide. C R Acad Sci Paris III 315:545-550.
5. Comte L, Lorgeot V, Volkov L, Allegraud A, Aldigier JC and Praloran V (1997) Effects of the angiotensin-converting enzyme inhibitor enalapril on blood haematopoietic progenitors and acetyl-N-Ser-Asp-Lys-Pro concentrations. Eur J Clin Inv 27:788-790.
6. Corvol P, Williams TA and Soubrier F (1995) Peptidyl dipeptidase A: Angiotensin I-converting enzyme. Methods Enzymol 248:283-305.
7. Cushman DW, Wang FL, Fung WC, Harvey CM and DeForrest JM (1989) Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens 2:294-306.
8. Endoh M, Suzuki M, Katayama K, Kakemi M and Koizumi T (1989) Kinetic studies of the pharmacologic response to captopril in rats. Hypotensive effect and plasma angiotensin converting enzyme activity. J Pharmacobio-Dyn 12:10-17.
9. Ezan E, Carde P, Le Kerneau J, Ardouin T, Thomas F, Isnard F, Deschamp de Paillette E and Grognet JM (1994) Pharmacokinetics in healthy volunteers and patients of N-AcSDKP (seraspenide), a negative regulator of hematopoiesis. Drug Metab Dispos 22:843-848.
10. Koike G, Krieger JE and Jacob HJ (1994) Angiotensin converting enzyme and genetic hypertension: Cloning of rat cDNAs and characterization of the enzyme. Biochem Biophys Res Commun 198:380-386.
11. Lenfant M, Wdzieczak-Bakala J, Guittet E, Prome JC, Sotty D and Frindel E (1989) Inhibitor of hematopoietic pluripotent stem cell proliferation: Purification and determination of its structure. Proc Natl Acad Sci USA 86:779-782.
12. Lin JH (1995) Species similarities and differences in pharmacokinetics. Drug Metab Dispos 23:1008-1018.
13. Menard J and Catt KJ (1972) Measurement of renin activity and substrate by radioimmunoassay of angiotensin I. Endocrinology 90:422-430.
14. Michaud A, Williams TA, Chauvet MT and Corvol P (1997) Substrate dependence of angiotensin I-converting enzyme inhibition: Captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I. Mol Pharmacol 51:1070-1076.
15. Pereira CD, Tam YK, Coe JY, Olley PM and Collins-Nakai RL (1996) Pharmacokinetic-pharmacodynamic modelling for captopril in healthy anaesthetized piglets. Biopharm Drug Dispos 17:365-372.
16. Perich RB, Jackson B and Johnston CI (1992) Variation in angiotensin-converting enzyme (ACE) inhibitor affinity at two binding sites on rat pulmonary ACE: Influence on bradykinin hydrolysis. Clin Exp Pharmacol Physiol 19:353-357.
17. Pradelles P, Frobert Y, Creminon C, Liozon E, Massé A and Frindel E (1990) Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analyzed by enzyme immunoassay. Biochem Biophys Res Commun 170:986-993.
18. Rieger KJ, Saez-Servent N, Papet MP, Wdzieczak-Bakala J, Morgat JL, Thierry J, Voelter W and Lenfant M (1993) Involvement of human plasma angiotensin I converting enzyme in the degradation of the haemoregulatory peptide N-Acetyl-Seryl-Aspartyl-Lysyl-Proline. Biochem J 296:1-6.
19. Robinson S, Lenfant M, Wdzieczak-Bakala J, Melville J and Riches A (1992) The mechanism of action of the tetrapeptide N-acetyl-Ser-Asp-Lys-Pro (AcSDKP) in the control of haematopoietic stem cell. Cell Proliferation 25:623-632.
20. Rousseau A, Michaud A, Chauvet MA, Lenfant M and Corvol P (1995) The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin converting enzyme. J Biol Chem 270:3656-3661.
21. Rousseau-Plasse A, Wdzieczak-Bakala J, Lenfant M, Ezan E, Genet R, Robinson S, Briscoe T, Melville J and Riches A (1998) Lisinopril, an angiotensin I-converting enzyme inhibitor, prevents stem cells into the cell cycle after irradiation in vivo. Exp Hematol 28:1074-1079.
22. Wei L, Clauser E, Alhenc-Gelas F and Corvol P (1992) The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem 267:13398-13405.